<?xml version="1.0"?>
<table>
  <tr>
    <td>AC-0 - Negative</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1502462422-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502462422-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1502462439-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502462439-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1502462497-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502462497-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1502718949-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502718949-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505097615-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505097615-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        <p>&#xD;
These images are provided as examples of what are considered as ANA-negative as viewed under a microscope. Since a negative ANA can be represented by a number of different images, it should be clear that AC-0 should not be regarded as the definite example but used for comparison purposes only. The guiding feature that links these variable possibilities is the absence of a clear-cut staining in any given subcellular structure. This definition is both subjective and semi-quantitative at best.&#xD;
</p>&#xD;
<p>&#xD;
There should be a discussion regarding how ANA-positive vs ANA-negative cut-off is determined. There are general consensus that such cut-offs should be determined experimentally and locally with normal population controls. The cut-off is highly dependent on the HEp-2 substrates used by individual laboratories, including factors specific to HEp-2 slide manufacturers and lot-to-lot variations, fluorochrome conjugated secondary antibody reagents, microscope and camera settings, serum dilutions, and other variables. &#xD;
</p>&#xD;
<p>&#xD;
In viewing these AC-0 images online using a computer screen, note that the screen default brightness setting may vary from computer to computer and some adjustment may be necessary for appropriate interpretation.  For computer with two screens, the brightness for both screen is not necessary in sync either. These AC-0 images are selected to show some definition of cells, including cells in metaphase. If one cannot see sufficient details, probably the screen brightness is set too dark.  On the other hand, if these images show too much green staining, please consider the screen brightness is set too bright.  In summary, viewers of these images on computer screen should make appropriate adjustment in their screen brightness setting accordingly.&#xD;
</p>&#xD;
<p>&#xD;
Please note that when these AC-0 images are downloaded and viewing with PC/Mac computers, there may be additional variations depending on the image viewing software, in addition to screen brightness setting as discussed above.&#xD;
</p>&#xD;
<p>&#xD;
See Herold et al. for full discussion (Clin Chem Lab Med. 2018;56:1799-802.)&#xD;
</p>&#xD;
<p>&#xD;
Herold M, Klotz W, Andrade LEC, Conrad K, de Melo Cruvinel W, Damoiseaux J, Fritzler MJ, von Muhlen CA, Satoh M, Chan EKL. International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. Clin Chem Lab Med. 2018;56:1799-802.&#xD;
</p>                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>Not applicable</td>
                                </tr>
</table>
<table class="table">
  <tr><td><strong>FAQ</strong></td>
                        </tr>
  <tr><td style="border: 0;">

                                <div class="containerFAQ">
<div id="pergunta233" class="pergunta" data-id="233" title="Click to show answer" alt="Click to show answer">
<div class="icone-faq"><i class="fa fa-plus"/></div>
<div class="texto-faq">
<b>How to deal with just a &#x201C;nuclear speckled&#x201D; IFA report?</b><div>
<b/>In my practice I have followed patients with ANA findings, with a nuclear speckled pattern (without specifying whether fine/dense/coarse), in patients with very heterogeneous phenotypes, some with a clinical picture that suggests further investigation of systemic autoimmune disease (one patient with proximal muscle weakness and skin thickening) and others who represent only non-specific findings. In such situations, as a precaution, I request more specific autoantibodies. However, this pattern (nuclear speckled pattern) is not described by the "ICAP" and I am in doubt about which antigenic association it represents, even to guide which autoantibody may be present and which ones to look after.  How to interpret this pattern? Does the lab describe it when it is not possible to "refine" such a conclusion? Could this be associated with deficiency in the methodology, sample, interpretation?<b><br/></b>
</div>
</div>
</div>
<div id="resposta233" class="resposta" style="display:none;">
<p>The term "nuclear speckled" is an overarching competent- HEp-2 IFA pattern that includes both fine speckled (AC-4) and large/coarse speckled (AC-5).  In some cases, it can be difficult to define precisely the speckled pattern a sample produces, being either the fine or large/coarse speckled pattern. Obviously, one may use the ICAP competent level terminology AC-4/5. In such case, one may combine the antibody targets and clinical relevance of the individual patterns, i.e., AC-4 and AC-5. Using the competent level AC-4/5 term may also be appropriate in mixed patterns caused by more than one autoantibody specificity in the sample. <br/>Ideally, one should provide the most complete definition of the pattern (expert level), because these provide more specific information on antigenic associations and clinical relevance. For example, as indicated in the "antigen association section" of ICAP website, the nuclear coarse speckled pattern (AC-5) is associated mainly with anti-Sm and anti-U1-RNP antibodies, whereas the nuclear fine speckled pattern (AC-4) has a broader target antigen association. In the ICAP Note #2, AC-4 can be further divided into fine speckled with myriad discrete tiny dots (AC-4a), or simple fine speckled (AC-4b). These are defined patterns and have respective antibody targets, immunological associations, and clinical relevance. The nuclear dense fine speckled pattern (AC-2), on the other hand, should be distinguished from the nuclear speckled patterns AC-4 and AC-5 based on the positive staining of the metaphase plate. With exception of the centromeric pattern (AC-3), the clinical relevance of all patterns is only indicated if the antibody target has been identified. <br/><br/></p>
<br/><strong>Date: </strong>August 5, 2023</div>
</div>
                            </td>

                        </tr>
</table>
<table>
  <tr>
    <td>AC-1 - Nuclear homogeneous</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302187-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302187-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306947-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306947-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346177-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346177-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617151987-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617151987-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625699092-0.jpg?1728523227" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699092-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>Diffuse</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Homogeneous and regular fluorescence across all nucleoplasm. The nucleoli maybe stained or not stained depending on cell substrate. Mitotic cells (metaphase, anaphase, and telophase) have the chromatin mass intensely stained in a homogeneous hyaline fashion.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>dsDNA, nucleosomes, histones</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with SLE, chronic autoimmune hepatitis or juvenile idiopathic arthritis</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SLE is clinically suspected, it is recommended to perform a follow-up test for anti-dsDNA antibodies, alone or in combination with dsDNA/histone complexes (nucleosomes/chromatin); anti-dsDNA antibodies are included in the classification criteria for SLE (15, 16)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If chronic autoimmune hepatitis or juvenile idiopathic arthritis is suspected, follow-up testing is not recommended because the respective autoantigens revealing the AC-1 pattern are not completely defined (17)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true">Notes: Although autoantibodies to Topoisomerase I (formerly Scl-70) may be reported as nuclear homogeneous, they typically reveal a composite AC-29 HEp-2 IIFA pattern; as such, clinical suspicion of SSc may warrant follow-up testing for reactivity to this antigen (14, 18)</div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true">Although AC-1 is the most prevalent pattern in chronic autoimmune hepatitis, other HEp-2 IIFA patterns may occur, but also for these patterns the autoantigens are not completely defined (19)</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">14.</div>
<div class="cr-content">Andrade LEC, Klotz W, Herold M, et al. International consensus on antinuclear antibody patterns: definition of the ac-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 2018;56:1783-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in systemic autoimmune diseases: a diagnostic reference. 2. 3th edn. Autoantigens autoantibodies autoimmunity, 2015.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">16.</div>
<div class="cr-content">Petri M, Orbai AM, Alarc&#xF3;n GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in organ specific autoimmune diseases. a diagnostic reference. 8. 2th edn. Autoantigens autoantibodies autoimmunity, 2017.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">18.</div>
<div class="cr-content">Dellavance A, Gallindo C, Soares MG, et al. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology 2009;48:632-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">19.</div>
<div class="cr-content">European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63:971-1004.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-2 - Nuclear dense fine speckled</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302361-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302361-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302380-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302380-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505097674-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505097674-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152044-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152044-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625699150-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699150-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Speckled pattern distributed throughout the interphase nucleus with characteristic heterogeneity in the size, brightness and distribution of the speckles. Throughout the interphase nucleus, there are some denser and looser areas of speckles (very characteristic feature). The metaphase plate depicts strong speckled pattern with some coarse speckles standing out.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>DFS70/LEDGF</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Commonly found as high titer HEp-2 IIFA-positive in apparently healthy individuals or in patients who do not have a systemic autoimmune rheumatic disease (SARD) (9)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The negative association with SARD is only valid if the autoreactivity is confirmed as being directed to DFS70 (also known as LEDGF/p75) and if no other common ENA is recognized (20, 21)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Both in apparently healthy individuals as well as patients who do not have a SARD the AC-2 pattern may be caused by autoantibodies to other antigens than DFS70 (22)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true">Note: Confirmatory assays for anti-DFS70 antibodies may be available only in specialty clinical laboratories.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">9.</div>
<div class="cr-content">Mariz HA, Sato EI, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis &amp; Rheumatism 2011;63:191-200.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">20.</div>
<div class="cr-content">Watanabe A, Kodera M, Sugiura K, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892-900.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">21.</div>
<div class="cr-content">Mahler M, Parker T, Peebles CL, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104-10.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">22.</div>
<div class="cr-content">Ochs RL, Mahler M, Basu A, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 2016;16:273-93.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-3 - Centromere</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302467-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302467-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302479-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302479-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302490-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302490-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346483-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346483-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625699243-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699243-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>Kinetochore</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Discrete coarse speckles (40-80/cell) scattered in interphase cells and aligned at the chromatin mass on mitotic cells. e.g. anti-CENP-B                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>CENP-A/B (C)</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Commonly found in patients with limited cutaneous SSc, and as such included in the classification criteria for SSc (8, 15, 23)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>In combination with Raynaud phenomenon, the AC-3 pattern is predictive for onset of limited cutaneous SSc (15, 23)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Strongly associated with antibodies to CENP-B; the CENP-B antigen is included in many routine multi-analyte solid phase immunoassay profiles (15); especially in case of low titers, confirmation by an antigen-specific solid phase immunoassay is recommended; </p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-3 pattern is also observed in a subset of patients with PBC; these patients often have both SSc as well as PBC (15)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in systemic autoimmune diseases: a diagnostic reference. 2. 3th edn. Autoantigens autoantibodies autoimmunity, 2015. </div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">23.</div>
<div class="cr-content">Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 2012;64:358-67</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC-3 pattern is reported in a subset of patients with SjS; these patients show mild SSc features, but a full-blown SjS clinical feature, more severe exocrine glandular dysfunction, and high risk of lymphoma (1-4)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC-3 pattern is also reported in a subset of patients with SLE; these patients often have some degree of overlap with SSc (5)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Most sera with the AC-3 pattern react with CENP-A and CENP-B; antibodies to CENP-A can be detected in some disease specific solid phase immunoassays (i.e., SSc profile) (6, 7)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>In rare cases AC-3 positive, but CENP-B negative sera of SSc patients may be strongly positive for anti-CENP-A antibodies (8, 9)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Antibodies to CENP-C have been reported in patients with SSc and SjS (10-11)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote">Note: Availability of assays for CENP-A, (i.e., ELISA or SSc profile) may be limited to specialty clinical laboratories; specific immunoassays for anti-CENP-C antibodies are currently not commercially available.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">1.</div>
<div class="cr-content">Vasiliki-Kallipi KB, Diamanti KD, Vlachoyiannopoulos PG, et al. Anticentromere antibody positive Sj&#xF6;gren&#xB4;s Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010;12:R47.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">2.</div>
<div class="cr-content">Lee KE, Kang JH, Lee JW, et al. Anti-centromere antibody-positive Sj&#xF6;gren&#xB4;s syndrome: a distinct clinical subgroup? Int J Rheum Dis 2015;18:776-82.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">3.</div>
<div class="cr-content">Baldini C, Mosca M, Della Rossa A, et al. Overlap of ACA-positive systemic sclerosis and Sj&#xF6;gren&#xB4;s syndrome: a distinct clinical entity with mild organ involvement but a high risk of lymphoma. Clin Exp Rheumatol 2013;31:272-80.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">4.</div>
<div class="cr-content">Baer AN, Medrano L, McAdams-Demarco M, et al. Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sj&#xF6;gren&#xB4;s syndrome: analysis of the Sj&#xF6;gren&#xB4;s International Collaborative Clinical Alliance Cohort. Arthritis Care Res 2016;68:1554-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">5.</div>
<div class="cr-content">Nakano M, Ohuchi Y, Hasegawa H, et al. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 2000;27:1403-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">6.</div>
<div class="cr-content">Perosa F, Prete M, Di Lernia G, et al. Anti-centromere protein A antibodies in systemic sclerosis: significance and origin. Autoimmun Rev 2016;15:102-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">7.</div>
<div class="cr-content">Mahler M, Maes L, Blockmans D, et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010;12:R99.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">Russo K, Hoch S, Varga J, et al. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuese and limited systemic sclerosis, systemic lupus erythematosis, and rheumatoid arthritis. J Rheumatol 2000;27:142-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">9.</div>
<div class="cr-content">Hudson M, Mahler M, Pope J, et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012;39:787-94.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">10.</div>
<div class="cr-content">Pillemer SR, Casciola-Rosen L, Baum BJ, et al. Centromere protein C is a target of autoantibodies in Sjogren's syndrome and is uniformly associated with antibodies to Ro and La. J Rheumatol 2004;31:1121-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">11.</div>
<div class="cr-content">Gelber AC, Pillemer SR, Baum BJ, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis 2006;65:1028-32.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-4 - Nuclear fine speckled</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302555-1.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302555-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505097718-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505097718-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600378-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600378-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1536360230-0.jpeg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1536360230-0.jpeg" width="180" height="180"/></a><a href="imgNew/prontas/1625699327-0.jpg?1728523228" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699327-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>fine granular</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Fine tiny speckles across all nucleoplasm. The nucleoli may be stained or not stained. Mitotic cells (metaphase, anaphase, and telophase) have the chromatin mass not stained. e.g. anti-SS-A/Ro, anti-SS-B/La                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>SS-A/Ro, SS-B/La, Mi-2, TIF1&#x3B3;, TIF1&#x3B2;, Ku</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Present to a varying degree in distinct SARD, in particular SjS, SLE, subacute cutaneous lupus erythematosus, neonatal lupus erythematosus, congenital heart block, DM, SSc, and SSc-AIM overlap syndrome (15)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SjS, SLE, subacute cutaneous lupus erythematosus, neonatal lupus erythematosus, or congenital heart block is clinically suspected, it is recommended to perform follow-up tests for anti-SS-A/Ro (Ro60) and anti-SS-B/La antibodies; in most laboratories these antigens are included in the routine ENA profile (15)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Autoantibodies to SS-A/Ro are part of the classification criteria for SjS (the criteria do not distinguish between Ro60 and Ro52/TRIM21) (25)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SSc, AIM, or to a lesser extend SLE, is clinically suspected, it is recommended to perform follow-up tests for detecting autoantibodies to Mi-2, TIF1&#x3B3;, and Ku; these antigens are typically included in disease specific immunoassays (i.e., inflammatory myopathy profile*) (26)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Autoantibodies to Mi-2 and TIF1&#x3B3; are associated with DM; autoantibodies to TIF1&#x3B3; in patients with DM, although rare in the overall AC-4 pattern, is strongly associated with malignancy in old patients (26, 27)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Autoantibodies to Ku are associated with SSc-AIM and SLE-SSc-AIM overlap syndromes (26)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Note: Anti-SS-A/Ro (Ro60) and AIM-specific autoantibodies may be undetected in HEp-2 IIFA-screening (28)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content " testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in systemic autoimmune diseases: a diagnostic reference. 2. 3th edn. Autoantigens autoantibodies autoimmunity, 2015.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">25.</div>
<div class="cr-content">Shiboski CH, Shiboski SC, Seror R, et al. American College of Rheumatology/European League against rheumatism classification criteria for primary Sj&#xF6;gren&#xB4;s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2016;2017:9-16.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">26.</div>
<div class="cr-content">Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">27.</div>
<div class="cr-content">Trallero-Aragu&#xE1;s E, Rodrigo-Pend&#xE1;s J&#xC1;, Selva-O&#xB4;Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64:523-32.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">28.</div>
<div class="cr-content">Bossuyt X, Frans J, Hendrickx A, et al. Detection of anti-SSA antibodies by indirect immunofluorescence. Clin Chem 2004;50:2361-9.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-5 - Nuclear large/coarse speckled</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302619-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302619-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302619-1.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302619-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505097854-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505097854-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152146-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152146-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625699513-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699513-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>spliceosome/nuclear matrix</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Coarse speckles across all nucleoplasm. The nucleoli may be stained or not stained. Mitotic cells (metaphase, anaphase, and telophase) have the chromatin mass not stained. e.g. anti-Sm, anti-U1 RNP                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>hnRNP, U1RNP, Sm, RNA polymerase III</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Present to a varying degree in distinct SARD, in particular SLE, SSc, MCTD, SSc-AIM overlap syndrome, and UCTD (i.e, patients with rheumatic symptoms without a definite SARD diagnosis) (29)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SLE is clinically suspected, it is recommended to perform follow-up tests for anti-Sm and anti-U1RNP antibodies; these antigens are commonly included in the routine ENA profile; anti-Sm antibodies are included in the classification criteria for SLE (16, 30, 31)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SSc is clinically suspected, it is recommended to perform a follow-up test for anti-RNApol III antibodies (e.g., SSc profile*); the anti-RNApol III antibodies are included in the classification criteria for SSc (8)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If MCTD is clinically suspected, it is recommended to perform a follow-up test for anti-U1RNP antibodies; the antigen is commonly included in the routine ENA profile; anti-U1RNP antibodies are included in the diagnostic criteria for MCTD (32)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If the SSc-AIM overlap syndrome is clinically suspected, it is recommended to perform follow-up tests for anti-U1RNP and anti-Ku antibodies; these antigens are included in the routine ENA profile (U1RNP), or in disease specific immunoassays (Ku, i.e., inflammatory myopathy profile* and SSc profile*) (26, 33)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>In non-SARD individuals in the general population, the presence of the AC-5 pattern is not associated with the autoantigens mentioned above and most often concerns low antibody titers</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">16.</div>
<div class="cr-content">Petri M, Orbai AM, Alarc&#xF3;n GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">26.</div>
<div class="cr-content">Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">29.</div>
<div class="cr-content">Northway JD, Tan EM. Differentiation of antinuclear antibodies giving Speckled staining patterns in immunofluorescence. Clin Immunol Immunopathol 1972;1:140-54.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">30.</div>
<div class="cr-content">Satoh M, Fritzler MJ, Chan EKL. Antihistone and antispliceosomal antibodies. In: Lahita RG, Tsokos G, Buyon JP, et al, eds. Systemic lupus erythematosus. San Diego: Academic Press, 2011: 275-92.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">31.</div>
<div class="cr-content">Satoh M, V&#xC3;&#xA1;zquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009;19:219-28.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">32.</div>
<div class="cr-content">Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Occasionally, autoantibodies revealing the AC&#x2010;5 pattern are reactive with RNP other than U1RNP, for instance U2RNP (associated with SSc&#x2010;AIM overlap syndrome) or U11/U12RNP (associated with SSc); these autoantibodies can be detected by immunoprecipitation (13, 14).</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Note: Specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">13.</div>
<div class="cr-content">Mimori T, Hinterberger M, Pettersson I, et al. Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome. J Biol Chem 1984;259:560-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">14.</div>
<div class="cr-content">Fretig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009;61:958-65.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-6 - Multiple nuclear dots</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473302657-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302657-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302781-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302781-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473302845-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473302845-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098378-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098378-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625699575-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625699575-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>6-20 nuclear dots, NSpI, PML bodies</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Countable discrete nuclear speckles (6 to 20 nuclear dots/cell). e.g. SP-100                                     </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>Sp-100, PML proteins, MJ/NXP-2</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in a broad spectrum of autoimmune diseases, including PBC, AIM (DM), as well as other inflammatory conditions (34)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If PBC is clinically suspected, it is recommended to perform follow-up tests for anti-Sp100 (and PML/Sp140) antibodies; in particular anti-Sp100 antibodies have the best clinical association with PBC and have added value, especially when associated with AMA; the Sp100 (and PML-Sp140) antigen is included in disease specific immunoassays (i.e., liver profile*) (17, 35, 36)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If DM is clinically suspected, it is recommended to perform a follow-up test for anti-MJ/NXP-2 antibodies; these anti-MJ/NXP-2 antibodies are highly specific for AIM, are found in up to one third of patients with juvenile DM, and have been reported to be associated with malignancies in adult AIM patients; the antigen is included in disease specific immunoassays (i.e., inflammatory myopathy profile*) (37&#x2013;39)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in organ specific autoimmune diseases. a diagnostic reference. 8. 2th edn. Autoantigens autoantibodies autoimmunity, 2017.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">34.</div>
<div class="cr-content">Cozzani E, Drosera M, Riva S, et al. Analysis of a multiple nuclear dots pattern in a large cohort of dermatological patients. Clin Lab 2012;58:329-32.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">35.</div>
<div class="cr-content">Hu SL, Zhao FR, Hu Q, et al. Meta-analysis assessment of gp210 and Sp100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014;9:e101916.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">36.</div>
<div class="cr-content">Granito A, Yang WH, Muratori L, et al. PML nuclear body component SP140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010;105:125-31.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">37.</div>
<div class="cr-content">Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710-3.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">38.</div>
<div class="cr-content">Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 2016;29:662-73.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">39.</div>
<div class="cr-content">Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012;14.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-7 - Few nuclear dots</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303112-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303112-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303112-1.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303112-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303112-2.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303112-2.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473307968-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473307968-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098074-0.jpg?1728523229" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098074-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>1 to 6 nuclear dots, coiled body, Cajal bodies</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Countable discrete speckles (1 to 6 nuclear dots/cell in most cells). These are known as Cajal bodies or coiled bodies. e.g. anti-p80-coilin                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>p80-coilin, SMN</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-7 pattern has low positive predictive value for any disease (40, 41)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens primarily localized in the dots include p80-coilin and SMN complex; specific immunoassays for these autoantibodies are currently not commercially available (42, 43)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">40.</div>
<div class="cr-content">Onouchi H, Muro Y, Tomita Y. Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. J Autoimmun 1999;13:225-32.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">41.</div>
<div class="cr-content">Fujimoto M, Kikuchi K, Tamaki T, et al. Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases. Br J Dermatol 1997;137:916-20.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">42.</div>
<div class="cr-content">Andrade LE, Chan EK, Raska I, et al. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin. J Exp Med 1991;173:1407-19.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">43.</div>
<div class="cr-content">Satoh M, Chan JY, Ross SJ, et al. Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. Arthritis Rheum 2011;63:1972-8.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Anti&#x2010;p80&#x2010;coilin antibodies may rarely occur in SLE, (localized linear) SSc, and SjS (15&#x2010;17)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Isolated (without anti&#x2010;snRNPs) anti&#x2010;SMN antibodies are reported in patients with AIM or SSc&#x2010;AIM overlap syndrome (18)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The specificity of antibodies to p80&#x2010;coilin and the SMN complex can be confirmed by Western blot, solid phase immunoassays using recombinant proteins and immunoprecipitation (15, 18, 19)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e. antigen&#x2010;specific immunoassays) and do not actually show clear correlations with the AC&#x2010;7 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Andrade LE, Chan EK, Raska I, et al. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin. J Exp Med 1991;173:1407-19.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">16.</div>
<div class="cr-content">Fujimoto M, Kikuchi K, Tamaki T, et al. Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases. Br J Dermatol 1997;137:916-20.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Onouchi H, Muro Y, Tomita Y. Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. J Autoimmun 1999;13:225-32.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">18.</div>
<div class="cr-content">Satoh M, Chan JY, Ross SJ, et al. Autoantibodies to survival of motor neuron (SMN) complex in patients with polymyositis - immunoprecipitation of D-EF-G without other components of small nuclear ribonucleoproteins. Arthritis Rheum 2011;63:1972-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">19.</div>
<div class="cr-content">Amlani A, Hazlewood GS, Hamilton L, et al. Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy. Rheumatology 2018;57:199-200.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-8 - Homogeneous nucleolar</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303186-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303186-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505097998-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505097998-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600429-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600429-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1536360826-0.jpeg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1536360826-0.jpeg" width="180" height="180"/></a><a href="imgNew/prontas/1625700030-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700030-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Diffuse fluorescence of the entire nucleolus, while the metaphase plate shows no staining. e.g. anti-PM-Scl, anti-Th/To.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>PM/Scl-75, PM/Scl-100, Th/To, B23/nucleophosmin, nucleolin, No55/SC65</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with SSc, SSc-AIM overlap syndrome, and patients with clinical manifestations of other SARD (44&#x2013;46)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If limited cutaneous SSc is clinically suspected, it is recommended to perform a follow-up test for anti-Th/To antibodies; the antigen is included in disease specific immunoassays (i.e., SSc profile*) (44, 45)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SSc-AIM overlap syndrome is clinically suspected, it is recommended to perform a follow-up test for anti-PM/Scl antibody reactivity; the antigen may be included in the routine ENA profile and is included in disease specific immunoassays (i.e., inflammatory myopathy profile* and the SSc profile*); in general, anti-PM/Scl antibodies yield a diffuse nuclear fine speckled staining in addition to the AC-8 pattern (46)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Other antigens recognized include B23/nucleophosmin, No55/SC65, and C23/nucleolin, but the clinical significance of these autoantibodies is not well established; specific immunoassays for these autoantibodies are currently not commercially available </p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Notes: Although some anti-Th/To antibody immunoassays are commercially available, technical issues relating to the limited sensitivity of these immunoassays should be taken in to consideration (44, 47). </p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">44.</div>
<div class="cr-content">Mahler M, Fritzler MJ, Satoh M. Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. Autoimmun Rev 2015;14:254-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">45.</div>
<div class="cr-content">Ceribelli A, Cavazzana I, Franceschini F, et al. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010;37:2071-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">46.</div>
<div class="cr-content">Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007;6:432-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">47.</div>
<div class="cr-content">Mahler M, Gascon C, Patel S, et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 2013;15.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC&#x2010;8 pattern that is the result of the anti&#x2010;Th/To reactivity is also seen in patients with SLE, UCTD (i.e., patients with rheumatic symptoms without a SARD diagnosis), SSc sine scleroderma, idiopathic interstitial lung disease or pulmonary hypertension (20, 21)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Patients with autoantibodies revealing the AC&#x2010;8 pattern due to anti&#x2010;PM/Scl reactivity may have, in addition to the clinical features of AIM and SSc, various clinical manifestations of SLE and SjS (22)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">20.</div>
<div class="cr-content">Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-Th/To-Positivity in a Cohort of Patients with Idiopathic Pulmonary Fibrosis. J Rheumatol 2006;33:1600-1605.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">21.</div>
<div class="cr-content">Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006;130:976-981.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">22.</div>
<div class="cr-content">Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007;6:432-437.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-9 - Clumpy nucleolar</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303223-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303223-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303288-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303288-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346653-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346653-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1536360747-0.jpeg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1536360747-0.jpeg" width="180" height="180"/></a><a href="imgNew/prontas/1625700141-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700141-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Irregular staining of the nucleoli and Cajal bodies with a peri-chromosomal staining at the metaphase plates. e.g. anti-fibrillarin.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>U3-snoRNP/fibrillarin</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with SSc (48)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SSc is clinically suspected, it is recommended to perform a follow-up test for anti-U3RNP/fibrillarin antibodies; the antigen is included in disease specific immunoassays (i.e., SSc profile*) (48)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If confirmed as anti-U3RNP/fibrillarin reactivity by immunoassay, the clinical association is with diffuse SSc, increased incidence of pulmonary arterial hypertension, skeletal muscle disease, severe cardiac involvement, and gastrointestinal dysmotility (23, 48&#x2013;50)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Among SSc patients, anti-U3RNP/fibrillarin antibodies are most commonly found in African American and Latin American patients (48, 49, 51)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Notes: Although some anti-U3RNP/fibrillarin immunoassays are commercially available, technical issues relating to the limited sensitivity of these immunoassays should be taken into consideration (24).</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">23.</div>
<div class="cr-content">Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 2012;64:358-67.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">24.</div>
<div class="cr-content">Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12:340-54.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">48.</div>
<div class="cr-content">Okano Y, Steen VD, Medsger TA. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">49.</div>
<div class="cr-content">Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">50.</div>
<div class="cr-content">Tormey VJ, Bunn CC, Denton CP, et al. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001;40:1157-62.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">51.</div>
<div class="cr-content">Nandiwada SL, Peterson LK, Mayes MD, et al. Ethnic differences in autoantibody diversity and hierarchy: More clues from a US cohort of patients with systemic sclerosis. J Rheumatol 2016;43:1816-24.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-10 - Punctate nucleolar</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303336-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303336-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303368-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303368-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473309686-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473309686-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473309724-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473309724-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346664-0.jpg?1728523230" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346664-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>nucleolar speckled</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Densely distributed but distinct grains seen in the nucleoli of interphase cells. In metaphase cells, up to 5 bright pairs of the nucleolar organizer regions (NOR) can be seen within the chromatin body. The cytoplasm of mitotic cells may be slightly positive. e.g. anti-NOR-90, anti-RNA polymerase I                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>RNA polymerase I, hUBF/NOR-90</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-10 pattern can be seen in various conditions, including SSc, Raynaud&#x2019;s phenomenon, SjS, and cancer (52&#x2013;56)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If the AC-10 pattern is observed in the serum of patients with conditions mentioned above, follow-up testing for anti-NOR90(hUBF) antibodies is to be considered; the antigen is included in disease specific immunoassays (i.e. SSc profile*) (54, 55)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>While AC-10 is associated with anti-RNApol I antibodies, these antibodies almost always coexist with anti-RNApol III antibodies which reveal the AC-5 pattern; therefore, if SSc is clinically suspected, it is recommended to perform a follow-up test for anti-RNApol III antibodies (See also AC-5); specific immunoassays for anti-RNApol I antibodies are currently not commercially available (52, 53, 57)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">52.</div>
<div class="cr-content">Reimer G, Rose KM, Scheer U, et al. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987;79:65-72.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">53.</div>
<div class="cr-content">vKuwana M, Kaburaki J, Mimori T, et al. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399-404.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">54.</div>
<div class="cr-content">Fritzler MJ, von Muhlen CA, Toffoli SM, et al. Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 1995;22:521-4.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">55.</div>
<div class="cr-content">Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor nor 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996;39:1313-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">56.</div>
<div class="cr-content">Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992;140:859-70.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">57.</div>
<div class="cr-content">Yamasaki Y, Honkanen-Scott M, Hernandez L, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006;54:3051-6.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-11 - Smooth nuclear envelope</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303426-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303426-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473308767-0.jpeg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473308767-0.jpeg" width="180" height="180"/></a><a href="imgNew/prontas/1473308781-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473308781-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346678-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346678-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152242-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152242-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>nuclear rim, nuclear membrane, membranous</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Homogeneous staining of the nucleus with greater intensity at its outer rim and no staining at the metaphase and anaphase chromatin plates. There is a peculiar accentuation of the fluorescence at the points where adjacent cells touch each other. e.g. anti-lamin B.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>lamins A,B,C, or lamin-associated proteins</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-11 pattern is infrequently found in routine autoantibody testing and has been described in autoimmune-cytopenias, autoimmune liver diseases, linear scleroderma, APS, and SARD; current information on clinical associations is based mainly on case reports and small cohorts (58&#x2013;60)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include lamins (A, B, C) and LAP-2; specific immunoassays for these autoantibodies are currently not commercially available (58&#x2013;60)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">58.</div>
<div class="cr-content">Coppo P, Clauvel JP, Bengoufa D, et al. Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides. Am J Hematol 2004;77:241-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">59.</div>
<div class="cr-content">Konstantinov K, Foisner R, Byrd D, et al. Integral membrane proteins associated with the nuclear lamina are novel autoimmune antigens of the nuclear envelope. Clin Immunol Immunopathol 1995;74:89-99.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">60.</div>
<div class="cr-content">Reeves WH, Chaudhary N, Salerno A, et al. Lamin B autoantibodies in sera of certain patients with systemic lupus erythematosus. J Exp Med 1987;165:750-62.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-12 - Punctate nuclear envelope</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303631-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303631-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303632-1.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303632-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303645-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303645-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303645-1.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303645-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473308536-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473308536-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>Nuclear membrane pores</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Nuclear envelope reveals a punctate staining in interphase cells, with accentuation of fluorescence at the points where adjacent cells touch each other. No staining of the metaphase and anaphase chromatin plates. e.g. anti-gp210.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>nuclear pore complex proteins (i.e. gp210)</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with PBC, as well as patients with other autoimmune liver diseases and SARD (61)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If PBC is clinically suspected, it is recommended to perform a follow-up test for anti-gp210 antibodies; the antigen is included in disease specific immunoassays (i.e., extended liver profile*) (62&#x2013;64)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Other antigens recognized include p62 nucleoporin, LBR, and Tpr; specific immunoassays for these autoantibodies are currently not commercially available (65-68)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">61.</div>
<div class="cr-content">Miyachi K, Hankins RW, Matsushima H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003;20:247-54.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">62.</div>
<div class="cr-content">Courvalin JC, Lassoued K, Bartnik E, et al. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990;86:279-85.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">63.</div>
<div class="cr-content">Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein gp210. J Exp Med 1993;178:2237-42.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">64.</div>
<div class="cr-content">Bandin O, Courvalin JC, Poupon R, et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996;23:1020-4.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">65.</div>
<div class="cr-content">Wesierska-Gadek J, Klima A, Komina O, et al. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann N Y Acad Sci 2007;1109:519-30.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">66.</div>
<div class="cr-content">Kraemer DM, Tony HP. Nuclear pore protein p62 autoantibodies in systemic lupus erythematosus. Open Rheumatol J 2010;4:24-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">67.</div>
<div class="cr-content">Courvalin JC, Lassoued K, Worman HJ, et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990;172:961-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">68.</div>
<div class="cr-content">Ou Y, Enarson P, Rattner JB, et al. The nuclear pore complex protein TPR is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence. Clin Exp Immunol 2004;136:379-87.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Anti&#x2010;p62 nucleoporin antibodies have been described in PBC and SLE (23, 24)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Anti&#x2010;LBR antibodies have been described in PBC (25)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Anti&#x2010;Tpr antibodies have been described in PBC, autoimmune liver disease, SLE, SSc and SjS (26)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e., antigen&#x2010;specific immunoassays) and do not actually show clear correlations with the AC&#x2010;12 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">23.</div>
<div class="cr-content">Wesierska-Gadek J, Klima A, Komina O, et al. Characterization of Autoantibodies against Components of the Nuclear Pore Complexes: High Frequency of Anti-p62 Nucleoporin Antibodies. Ann NY Acad Sci 2007;1109:519-30.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">24.</div>
<div class="cr-content">Kraemer DM, Tony H-P. Nuclear Pore Protein p62 Autoantibodies in Systemic Lupus Erythematosus. Open Rheumatol J 2010;4:24-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">25.</div>
<div class="cr-content">Courvalin J-C, Lassoued K, Worman HJ, et al. Identification and Characterization of Autoantibodies Against the Nuclear Envelope Lamin B Receptor from Patients with Primary Biliary Cirrhosis. J Exp Med 1990;172:961-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">26.</div>
<div class="cr-content">Ou Y, Enarson P, Rattner JB, et al. The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence. Clin Exp Immunol 2004;136:379-87.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-13 - PCNA-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303722-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303722-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303809-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303809-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346781-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346781-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520509442-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520509442-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600573-0.jpg?1728523231" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600573-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Pleomorphic speckled nucleoplasmic staining, with variability in size and brightness of the speckles. In interphase, some cells are negative (G1 phase), some are intensely stained (S-phase) and some present rare and scattered speckles with occasional nucleolar staining (late S and early G2 phases). Mitotic cells are not stained.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>PCNA</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-13 pattern has formerly been considered highly specific for SLE, but this specificity is debated (69, 70)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SLE is clinically suspected, it is recommended to perform a follow-up test for anti-PCNA antibodies; the antigen is included in several routine ENA profiles (69)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Recent studies with antigen-specific immunoassays show clinical associations also with SSc, AIM, RA, HCV, and other conditions (70&#x2013;73)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">69.</div>
<div class="cr-content">Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978;121:2228-34.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">70.</div>
<div class="cr-content">Vermeersch P, De Beeck KO, Lauwerys BR, et al. Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus. Ann Rheum Dis 2009;68:1791-3.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">71.</div>
<div class="cr-content">Mahler M, Burlingame RW, Wu J, et al. Serological and clinical associations of anti-PCNA antibodies in systemic lupus erythematosus detected by a novel chemiluminescence assay. Arthritis Rheum 2011;63.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">72.</div>
<div class="cr-content">Mahler M, Miyachi K, Peebles C, et al. The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev 2012;11:771-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">73.</div>
<div class="cr-content">Hsu TC, Tsay GJ, Chen TY, et al. Anti-PCNA autoantibodies preferentially recognize C-terminal of PCNA in patients with chronic hepatitis B virus infection. Clin Exp Immunol 2006;144:110-6.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>A major challenge in deriving an association of the AC&#x2010;13 pattern with antibodies to the classical 35 kDa PCNA (elongation factor of DNA polymerase delta auxiliary protein) is that &#x201C;PCNA&#x201D; is known to be a macromolecular complex where targets other than the &#x2018;classical&#x2019; 35 kDa PCNA are present. In addition, a number of other apparently unrelated targets can also produce an AC&#x2010;13&#x2010;like pattern by HEp&#x2010;2 IIFA (27)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">27.</div>
<div class="cr-content">Takeuchi K, Kaneda K, Kawakami I, et al. Autoantibodies recognizing proteins copurified with PCNA in patients with connective tissue diseases. Mol Biol Rep 1996;23:243-6.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-14 - CENP-F-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473303877-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303877-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303877-1.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303877-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303922-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303922-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473303922-1.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473303922-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346790-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346790-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>MSA-3, NSp-II</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Nuclear speckled pattern with striking variability in intensity with the strongest staining in G2 phase and weakest/negative staining in G1. The centromeres are positive only in prometaphase and metaphase, revealing multiple aligned small and faint dots. Prometaphase cells frequently show a weak staining of the nuclear envelope. During anaphase and telophase, some sera demonstrate intense staining in the ring located at the midzone (i.e. mid-body, stem body) where the division of the daughter cells is taking place. The surrounding cytoplasm of the mitotic cells is diffusely stained.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>CENP-F</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The majority of sera exhibiting the AC-14 pattern are from patients with a diversity of neoplastic conditions (breast, lung, colon, lymphoma, ovary, brain); paradoxically, the frequency of the AC-14 pattern in patient cohorts with these malignancies is low</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-14 pattern is also seen in inflammatory conditions (Crohn&#x2019;s disease, autoimmune liver disease, SjS, graft-versus-host disease); current information on clinical associations is based mainly on case reports and series of cases</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Possible associations only hold if the reactivity to CENP-F is confirmed in an antigen-specific immunoassay; current information on clinical associations is based mainly on case reports and series of cases; specific immunoassays for this autoantibody are currently not commercially available (74&#x2013;78)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">74.</div>
<div class="cr-content">Casiano CA, Landberg G, Ochs RL, et al. Autoantibodies to a novel cell cycleregulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci 1993;106:1045-56.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">75.</div>
<div class="cr-content">Casiano CA, Humbel RL, Peebles C, et al. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun 1995;8:575-86.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">76.</div>
<div class="cr-content">Rattner JB, Rees J, Whitehead CM, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997;20:308-19.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">77.</div>
<div class="cr-content">Bencimon C, Salles G, Moreira A, et al. Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin&#xB4;s lymphoma. Ann N Y Acad Sci 2005;1050:319-26.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">78.</div>
<div class="cr-content">Welner S, Trier NH, Frisch M, et al. Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay. Mol Cancer 2013;12.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-15 - Cytoplasmic fibrillar linear</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473304507-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304507-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473304532-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304532-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346808-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346808-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152307-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152307-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>actin-like</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        This pattern is characterized by decorated cytoskeletal fibers, sometimes with small, discontinuous granular deposits. Typical staining show striated actin cables spanning the long axis of the cells. e.g. anti-actin, anti-non-muscle myosin.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>actin, non-muscle myosin</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with AIH type 1, chronic HCV infection, and celiac disease (IgA isotype); rare in SARD (17)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If AIH type 1 is clinically suspected, it is recommended to confirm reactivity with smooth muscle antibodies (IgG isotype), typically detected by IIFA on rodent tissue (liver, stomach, kidney); anti-smooth muscle antibodies are included in the international criteria for AIH type 1 (17,80)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>F-actin is the main target antigen of anti-smooth muscle antibodies in AIH type 1; autoantibodies to F-actin are of more clinical importance than antibodies to G-actin (81&#x2013;83)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true">Notes: Although anti-F-actin immunoassays are commercially available, technical issues relating to the sensitivity of these immunoassays should be taken into consideration.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Conrad K, Sch&#xF6;ssler W, Hiepe F. Autoantibodies in organ specific autoimmune diseases. a diagnostic reference. 8. 2th edn. Autoantigens autoantibodies autoimmunity, 2017.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">80.</div>
<div class="cr-content">Liberal R, Grant CR, Longhi MS, et al. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev 2014;13:435-40.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">81.</div>
<div class="cr-content">Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976;24:266-72.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">82.</div>
<div class="cr-content">Fusconi M, Cassani F, Zauli D, et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 1990;130:1-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">83.</div>
<div class="cr-content">Chretien-Leprince P, Ballot E, Andre C, et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci 2005;1050:266-73.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>High prevalence of IgA and/or IgG type anti-actin antibody has been reported in celiac disease (1, 2)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to non-muscle myosin have been described in 3 patients with HCV-positive chronic hepatitis/liver cirrhosis (3)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Monoclonal antibodies to non-muscle myosin have been reported in chronic lymphocytic leukemia (4).</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote">Note: Specific immunoassays for non-muscle myosin are currently not commercially available.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">1.</div>
<div class="cr-content">Pedreira S, Sugai E, Moreno ML, et al. Significance of smooth muscle/anti-actin autoantibodies in celiac disease. Acta Gastroenterol Latinoam 2005;35:83-93.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">2.</div>
<div class="cr-content">Clemente MG, Musu MP, Frau F, et al. Immune reaction against the cytoskeleton in coeliac disease. Gut 2000;47:520-6.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">3.</div>
<div class="cr-content">von Muhlen CA, Chan EKL, Peebles CL, et al. Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases. Clin Exp Immunol 1995;100:67-74.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">4.</div>
<div class="cr-content">Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112:5122-9.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-16 - Cytoplasmic fibrillar filamentous</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473304601-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304601-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473304655-1.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304655-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346828-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346828-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152380-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152380-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1626570418-0.jpg?1728523232" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1626570418-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Staining of microtubules and intermediate filaments spreading from the nuclear rim. e.g. anti-cytokeratin, anti-vimentin, anti-tropomyosin.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>vimentin, cytokeratins, tropomyosin</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in various diseases, but AC-16 is not typically found in SARD</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include cytokeratins 8, 18, &amp; 19, tubulin, and vimentin; specific immunoassays for these autoantibodies are currently not commercially available</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to cytokeratin 8, 18, 19:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Higher levels of anti-cytokeratin 8, anti-cytokeratin 18 and anti-cytokeratin 19 antibodies reported in patients with AIH compared with normal volunteers and patients with chronic active HCV infection (5)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibody against the 45-kDa human cytokeratin 18 protein reported in 76% of chronic obstructive pulmonary disease patients and 24% of control subjects (6)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Higher levels of anti-cytokeratin 19 antibodies reported in patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders compared with healthy controls, patients with chronic bronchitis, and patients with pneumonia (7)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to tubulin:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported in 50% of sera from patients with alcoholic liver disease, but in only 7 &#x2013; 13% of sera from patients with chronic active hepatitis, PBC, and healthy controls (8)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported in high prevalence in patients with certain parasitic infections (9)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>IgM autoantibodies to tubulin have been described in patients with infectious mononucleosis and healthy adults (10)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>IgG autoantibodies to tubulin have been detected specifically associated with young age onset of nasopharyngeal carcinoma (11)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported in a single case of a patient with a progressive sensorimotor neuropathy (12)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>High levels of polyclonal autoantibodies to tubulin are associated with acquired demyelinating polyneuropathies (13, 14)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Low levels of autoantibodies are reported in healthy controls (15)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported as one of the biomarkers for Sydenham&#x2019;s chorea and PANDAS syndrome (16)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content ">Autoantibodies to vimentin:</div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>IgG and IgM autoantibodies to vimentin have been reported as relevant markers in patients with neurofibromatosis type 1 and associated tumors (17)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Rheumatoid arthritis and other inflammatory arthritis patients may have antibody to citrullinated isoforms of vimentin; it is, however, unlikely that these antibodies show the AC-16 pattern (18)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported to occur after solid organ transplantation and implicated in rejection and poor outcome in cardiac or renal transplantation (19, 20)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e., antigen-specific immunoassays) and none actually shows correlations with the AC-16 pattern as such; specific immunoassay for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">5.</div>
<div class="cr-content">Murota M, Nishioka M, Fujita J, et al. Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis. Clin Exp Immunol 2001;125:291-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">6.</div>
<div class="cr-content">Kuo YB, Chang CA, Wu YK, et al. Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. Immunol Lett 2010;128:131-6.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">7.</div>
<div class="cr-content">Fujita J, Dobashi, N Ohtsuki Y, et al. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary&#xD;
fibrosis associated with collagen vascular disorders. Lung 1999;177:311-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">Kurki P, Miettinen A, Salaspuro M, et al. Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease. Hepatology 1983;3:297-302.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">9.</div>
<div class="cr-content">Howard MK, Gull K, Miles MA. Antibodies to tubulin in patients with parasitic infections. Clin Exp Immunol 1987;68:78-85.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">10.</div>
<div class="cr-content">Mead GM, Cowin P, Whitehouse JM. Antitubulin antibody in healthy adults and patients with infectious mononucleosis and its relationship to smooth muscle antibody (SMA). Clin Exp Immunol 1980;39:328-36.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">11.</div>
<div class="cr-content">Jalbout M, Bel Hadj Jrad B, Bouaouina N, et al. Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int J Cancer 2002;101:146-50.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">12.</div>
<div class="cr-content">Stubbs EB Jr., Fisher MA, Siegel GJ. Anti-tubulin antibodies in a sensorimotor neuropathy patient alter tubulin polymerization. Acta Neuropathol 1998;95:302-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">13.</div>
<div class="cr-content">Connolly AM, Pestronk A. Anti-tubulin autoantibodies in acquired demyelinating polyneuropathies. J Infect Dis 1997;176:S157-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">14.</div>
<div class="cr-content">Manfredini E, Nobile-Orazio E, Allaria S, et al. Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. J Neurol Sci 1995;133:79-84.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Karsenti E, Guilbert B, Bornens M, et al. Antibodies to tubulin in normal nonimmunized animals. Proc Natl Acad Sci U S A 1977;74:3997-4001.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">16.</div>
<div class="cr-content">Kirvan CA, Cox CJ, Swedo SE, et al. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007;178:7412-21.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Kotaska K, Petrak B, Kukacka J, et al. Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1. Neuro Endocrinol Lett 2007;28:761-4.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">18.</div>
<div class="cr-content">Tilleman K, Van Steendam K, Cantaert T, et al. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology 2008;47:597-604.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">19.</div>
<div class="cr-content">Mahesh B, Leong HS, McCormack A, et al. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007;170:1415-27.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">20.</div>
<div class="cr-content">Besarani D, Cerundolo L, Smith JD, et al. Role of anti-vimentin antibodies in renal transplantation. Transplantation 2014;98:72-8.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-17 - Cytoplasmic fibrillar segmental</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473304741-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304741-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473304743-1.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473304743-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600731-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600731-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Enhanced decoration of short segments, periodic dense bodies, along the stress fibers. e.g. anti-alpha-actinin, anti-vinculin.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>alpha-actinin, vinculin</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found very infrequently in a routine serology diagnostic setting</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include &#x3B1;-actinin and vinculin; specific immunoassays for these autoantibodies are currently not commercially available</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to &#x3B1;-actinin:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>In SLE and lupus nephritis cross-reactive anti-&#x3B1;-actinin and anti-dsDNA autoantibodies have been reported as pathogenic (21)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported as part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis; also reported as a biomarker to differentiate patients with lupus nephritis from those without renal involvement (22, 23)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported with relatively high prevalence (~40%) in patients with AIH type 1 and associated with more severe disease, clinical and histological disease activity, predictor of therapeutic response, and double positivity with anti-ssDNA antibodies (24-26)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to vinculin:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Reported in 2 of 31 patients with chronic inflammatory demyelinating neuropathy (27)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e. antigen-specific immunoassays) and none actually shows correlations with the AC-17 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">21.</div>
<div class="cr-content">Zhao Z, Weinstein E, Tuzova M, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005;52:522-30.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">22.</div>
<div class="cr-content">Seret G, Canas F, Pougnet-Di Costanzo L, et al. Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. J Autoimmun 2015;61:54-61.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">23.</div>
<div class="cr-content">Zhang WH, Pan HF, Zhao XF, et al. Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis. Mol Biol Rep 2010;37:1341-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">24.</div>
<div class="cr-content">Gueguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006;26:495-505.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">25.</div>
<div class="cr-content">Renaudineau Y, Dalekos GN, Gueguen P, et al. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008);34:321-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">26.</div>
<div class="cr-content">Zachou K, Oikonomou K, Renaudineau Y, et al. Anti-alpha actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012;35:116-25.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">27.</div>
<div class="cr-content">Beppu M, Sawai S, Satoh M, et al. Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2015;287:9-15. </div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-18 - Cytoplasmic discrete dots/GW body-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473305013-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305013-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305033-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305033-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098141-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098141-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152436-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152436-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625700204-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700204-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>GW body, processing body, lysosome*</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Staining of GW bodies in the cytoplasm of interphase cells with high numbers in late S/G2 cells. e.g. anti-GW182, anti-Su/Ago2.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>GW182, Su/Ago2, *no molecular evidence to support this pattern is associated with lysosomal targets</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Autoantibodies revealing the AC-18 pattern have been reported in distinct SARD and in a variety of other diseases; their prevalence in unselected or specified disease cohorts has not been thoroughly studied (84)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include GW-body (Processing or P body) antigens (Ge-1/Hedls, GW182, and Su/Ago2) and endosomal antigens (EEA1, CLIP-170, GRASP-1, and LBPA); specific immunoassays for these autoantibodies are currently not commercially available</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Notes: Autoantibodies to GW-bodies and endosomes may yield slightly different HEp-2 IIFA patterns (84, 85).</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">84.</div>
<div class="cr-content">Bhanji RA, Eystathioy T, Chan EK, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007;125:247-56.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">85.</div>
<div class="cr-content">Stinton LM, Eystathioy T, Selak S, et al. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol 2004;110:30-44.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to GW bodies:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The most common clinical presentations in a single study with 55 positive sera were neurological symptoms (i.e. ataxia, motor and sensory neuropathy; 33%), SjS (31%), and the remainder had a variety of other diagnoses including SLE, RA, and PBC (28)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Analysis by ALBIA and immunoprecipitation of recombinant proteins indicated that autoantibodies were directed against Ge-1/Hedls (58%), GW182 (40%), and Su/Ago2 (16%) (28)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker"/>
<div class="cr-content "><p>Autoantibodies to endosomal components:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to EEA1 were seen in a variety of conditions, but ~40% of the patients had a neurological disease (29)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to CLIP-170 were reported in 4 patients with different diseases including the prototype patient with SLE and AIM; the remaining 3 patients had limited cutaneous SSc, glioblastoma, and idiopathic pleural effusion (30)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to both LBPA and GRASP-1 have not been studied thoroughly in unselected or specified disease cohorts; anti-GRASP-1 autoantibodies were detected in 17% of PBC sera (31, 32)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describing autoantibodies directly binding to specific endosomal antigens do not show correlations with the AC-18 pattern as such; specific immunoassays for the autoantibodies reacting with antigens of GW bodies or endosomes are currently not commercially available. </p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">28.</div>
<div class="cr-content">Bhanji RA, Eystathioy T, Chan EKL, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007;125:247-56.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">29.</div>
<div class="cr-content">Stinton LM, Eystathioy T, Selak S, et al. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol 2004;110:30-44.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">30.</div>
<div class="cr-content">Griffith KJ, Ryan JP, Senecal JL, et al. The cytoplasmic linker protein CLIP-170 is a human autoantigen. Clin Exp Immunol 2002;127:533-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">31.</div>
<div class="cr-content">Stinton LM, Selak S, Fritzler MJ. Identification of GRASP-1 as a novel 97 kDa autoantigen localized to endosomes. Clin Immunol 2005;116:108-17.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">32.</div>
<div class="cr-content">Stinton LM, Swain M, Myers RP, et al. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2011;163:147-56.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-19 - Cytoplasmic dense fine speckled</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473305085-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305085-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305146-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305146-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305163-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305163-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346880-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346880-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152464-0.jpg?1728523233" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152464-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>cytoplasmic homogeneous</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        The pattern appears cloudy, almost homogeneous throughout the cytoplasm. e.g. anti-PL-7.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>PL-7, PL-12, ribosomal P proteins</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with SLE and the anti-synthetase syndrome (a subset of AIM), interstitial lung disease, polyarthritis, Raynaud&#x2019;s phenomenon, and mechanic&#x2019;s hands; these features may occur in various combinations or as an isolated manifestation, especially interstitial lung disease (33, 86, 87)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SLE is clinically suspected, follow-up tests for antibodies to ribosomal P phosphoproteins (P0, P1, P2, C22 RibP peptide) are recommended; these antigens may be included in the routine ENA profile</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Anti-RibP antibodies have been associated in some studies with neuropsychiatric lupus, and in childhood-onset SLE with autoimmune hemolytic anemia (86, 88, 89)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If AIM, in particular the anti-synthetase syndrome, is suspected, it is recommended to perform follow-up tests for antibodies to tRNA synthetases; antigens are included in disease specific immunoassays (i.e., inflammatory myopathy profile*) (26, 33)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If AIM, in particular necrotizing myopathy, is suspected, it is recommended to perform follow-up tests for anti-SRP antibodies; the antigen is included in disease specific immunoassays (i.e., inflammatory myopathy profile*) (26)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Notes: The fine distinction between AC-19 and -20 may depend on HEp-2 substrates and/or antibody concentration; antibodies to both RibP as well as tRNA synthetases may be undetected in HEp-2 IIFA-screening.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">26.</div>
<div class="cr-content">Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">33.</div>
<div class="cr-content">Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1-19.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">86.</div>
<div class="cr-content">Sciascia S, Bertolaccini ML, Roccatello D, et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol 2014;261:1706-14.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">87.</div>
<div class="cr-content">Yura H, Sakamoto N, Satoh M, et al. Clinical characteristics of patients with antiaminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir Med 2017;132:189-94.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">88.</div>
<div class="cr-content">Val&#xC3;&#xB5;es CC, Molinari BC, Pitta AC, et al. Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients. Lupus 2017;26:484-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">89.</div>
<div class="cr-content">Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006;13:77-83.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to RibP:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Anti-RibP antibodies have been reported in 10% of AIH patients without clinical or laboratory evidence of SLE (33)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The prevalence of anti-RibP antibodies in SLE has been reported to range between 8 &#x2013; 35% in a multicenter study (34)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Less than 60% of the sera positive for anti-RibP antibodies have the AC-19 pattern at serum screening dilutions of 1/80 or higher; the coexistence of a weak nucleolar staining is relatively common</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to tRNA-synthetases:</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Less than 50% of sera having anti-tRNA synthetase antibodies have an AC-19 pattern at serum screening dilutions of 1/80 or higher (35)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Note: Most reports describing clinical association of anti-RibP antibodies do not actually show correlations with the AC-19 pattern as such.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">33.</div>
<div class="cr-content">Calich AL, Viana VS, Cancado E, et al. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int 2013;33:909-13.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">34.</div>
<div class="cr-content">Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006;13:77-83.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">35.</div>
<div class="cr-content">Fritzler MJ, Choi MY, Mahler M. The anti-nuclear antibody (ANA) test in the diagnosis of anti-synthetase syndrome and other autoimmune myopathies (AIM). J Rheumatol 2018;45:444-5.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-20 - Cytoplasmic fine speckled</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473305217-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305217-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305217-1.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305217-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305237-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305237-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305237-1.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305237-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346896-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346896-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>cytoplasmic speckled</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Scattered small speckles in the cytoplasm mostly with homogeneous or dense fine speckled background. e.g. anti-Jo-1.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>Jo-1/histidyl-tRNA synthetase</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in patients with the anti-synthetase syndrome (a subset of AIM), interstitial lung disease, polyarthritis, Raynaud&#x2019;s phenomenon, and mechanic&#x2019;s hands; these features may occur in various combinations or as an isolated manifestation, especially interstitial lung disease (33, 90)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Autoantibodies associated with the AC-20 pattern are primarily reported for the anti-Jo-1 antibody, which recognizes histidyl-tRNA synthetase; since AC-20 is not specific for Jo-1, it is recommended to perform a follow-up test for anti-Jo-1 antibodies; the antigen is included in the routine ENA profile, as well as in disease specific immunoassays (i.e., inflammatory myopathy profile*); the anti-Jo-1 antibodies are included in the classification criteria for AIM (91, 92)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>Notes: The fine distinction between AC-19 and -20 may depend on HEp-2 substrates and/or antibody concentration; antibodies to Jo-1 may be undetected in HEp-2 IIFA-screening.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">33.</div>
<div class="cr-content">Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52:1-19.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">90.</div>
<div class="cr-content">Marie I, Hatron PY, Cherin P, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther 2013;15.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">91.</div>
<div class="cr-content">Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies. J Rheumatol 2018;45:444.1-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">92.</div>
<div class="cr-content">Lundberg IE, Tja&#xA8;rnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76:1955-64.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-21 - Cytoplasmic reticular/AMA</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473305288-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305288-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305347-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305347-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346907-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346907-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152533-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152533-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625700246-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700246-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>mitochondria-like</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Coarse granular filamentous staining extending throughout the cytoplasm. e.g. anti-mitochondrial antibodies.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>PDC-E2/M2, BCOADC-E2, OGDC-E2, E1&#x3B1; subunit of PDC, E3BP/protein X</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Commonly found in PBC, but also detected in SSc, including PBC-SSc overlap syndrome and PBC-SjS overlap syndrome (93&#x2013;97)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If PBC is clinically suspected it is recommended to perform a follow-up test for AMA, historically detected by IIFA on rodent tissue (liver, stomach, kidney); these autoantibodies are primarily directed to the PDH complex, and in particular the E2-subunit (PDH-E2); the antigen is included in disease specific immunoassays (i.e., liver profile*) as well as in some routine ENA profiles (93, 94)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Additional antigens recognized include the E1&#x3B1; and E1&#x3B2; subunits of PDH, the E3-binding protein of PDH, and the 2-OGDC; these antigens are only included in extended disease specific immunoassays (i.e., extended liver profile*) (93, 94)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true"><p>*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">93.</div>
<div class="cr-content">European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145-72.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">94.</div>
<div class="cr-content">Shuai Z, Wang J, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 2017;65:1670-82.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">95.</div>
<div class="cr-content">Skare TL, Nisihara RM, Haider O, et al. Liver autoantibodies in patients with scleroderma. Clin Rheumatol 2011;30:129-32.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">96.</div>
<div class="cr-content">Zheng B, Vincent C, Fritzler MJ, et al. Prevalence of systemic sclerosis in primary biliary cholangitis using the new ACR/EULAR classification criteria. J Rheumatol 2017;44:33-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">97.</div>
<div class="cr-content">Nardi N, Brito-Zer&#xC3;&#xB3;n P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sj&#xF6;gren&#xB4;s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006;25:341-6.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-22 - Polar/Golgi-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473305428-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305428-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473305449-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473305449-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473307796-1.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473307796-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1564361861-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1564361861-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152565-0.jpg?1728523234" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152565-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Discontinuous speckled or granular perinuclear ribbon-like staining with polar distribution in the cytoplasm. e.g. anti-giantin, anti-golgin-245.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>giantin/macrogolgin, golgin-95/GM130, golgin-160, golgin-97, golgin-245</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found in small numbers of patients with a variety of conditions</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include giantin/macrogolgin and distinct golgin molecules; specific immunoassays to detect autoantibodies directed to specific Golgi antigens are currently not commercially available (85)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">85.</div>
<div class="cr-content">Stinton LM, Eystathioy T, Selak S, et al. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol 2004;110:30-44.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC-22 pattern has been reported in small numbers of patients with a variety of conditions, including SjS, SLE, RA, MCTD, GPA, idiopathic cerebellar ataxia, paraneoplastic cerebellar degeneration, adult Still&#x2019;s disease, and viral infections including HIV and EBV (29, 36-38)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Although possibly biased by the referral pattern, one study concluded that the AC-22 pattern is not clinically associated with SARD as there were only 1 SjS and 2 RA diagnoses among their 20 AC-22 positive cases collected over 10-years and a clinical follow-up observation ranging from 0 &#x2013; 10 years; the remaining cases showed diverse diagnoses including 2 carcinomas (37)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC-22 pattern is rare in the general population (39)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">29.</div>
<div class="cr-content">Stinton LM, Eystathioy T, Selak S, et al. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol 2004;110:30-44.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">36.</div>
<div class="cr-content">Fritzler MJ, Etherington J, Sokolu, C, et al. Antibodies from patients with autoimmune disease react with a cytoplasmic antigen in the Golgi apparatus. J Immunol 1984;132:2904-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">37.</div>
<div class="cr-content">Vermeersch P, Van den Bergh K, Blockmans D, et al. Anti-Golgi autoantibodies are not clinically associated with systemic autoimmune diseases. Ann Rheum Dis 2011;70:234-5.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">38.</div>
<div class="cr-content">Staub HL, Souza F, Chan EKL, et al. Anti-Golgi antibodies in adult Still's disease. Clin Exp Rheumatol 2003;21:275-6.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">39.</div>
<div class="cr-content">Satoh M, Chan EKL, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319-27.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-23 - Rods and rings</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306070-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306070-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306086-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306086-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473307298-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473307298-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473307298-1.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473307298-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346971-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346971-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Distinct rod and ring structures in the cytoplasm of interphase cells. Some smaller rods and rings also reported in the nucleus.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>IMPDH2</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Most commonly found in HCV patients who have been treated with pegylated interferon-&#x3B1;/ribavirin combination therapy, but autoantibodies revealing the AC-23 patterns were undetected prior to treatment; as the use of interferon-&#x3B1;/ribavirin in HCV treatment is decreasing, the frequency and clinical associations of the AC-23 pattern may change (98&#x2013;101)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Specific immunoassays to detect autoantibodies directed to specific Rods and Rings antigens, for instance IMPDH2, are not commercially available </p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote" testejc="true">Note: Presence of the AC-23 pattern depends on the HEp-2 cell substrate.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">98.</div>
<div class="cr-content"><p>Covini G, Carcamo WC, Bredi E, et al. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther 2012;17:805-11.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">99.</div>
<div class="cr-content"><p>Calise SJ, Keppeke GD, Andrade LE, et al. Anti-rods/rings: a human model of drug-induced autoantibody generation. Front Immunol 2015;6.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">100.</div>
<div class="cr-content"><p>Novembrino C, Aghemo A, Ferraris Fusarini C, et al. Interferon-ribavirin therapy induces serum antibodies determining &#xE2;&#x20AC;&#x2122;rods and rings&#xE2;&#x20AC;&#x2122; pattern in hepatitis C patients. J Viral Hepat 2014;21:944-9.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">101.</div>
<div class="cr-content"><p>Keppeke GD, Calise SJ, Chan EK, et al. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-&#xCE;&#xB1;/ribavirin therapy. World J Gastroenterol 2016;22:1966-74.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>HCV patients positive for the AC-23 pattern have been reported to have disease that is more resistant to therapy, but this is not confirmed in other cohorts (40)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>The AC-23 pattern has also been reported rarely in individuals without HCV infection, including SLE patients and patients under treatment with mycophenolic acid, azathioprine, methotrexate or acyclovir, as well as with lower titers in the general population (39-42)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">39.</div>
<div class="cr-content"><p>Satoh M, Chan EKL, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319-27.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">40.</div>
<div class="cr-content"><p>Climent J, Morandeira F, Castellote J, et al. Clinical correlates of the "rods and rings" antinuclear antibody pattern. Autoimmunity 2016;49:102-8.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">41.</div>
<div class="cr-content"><p>Covini G, Carcamo WC, Bredi E, et al. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther 2012;17:805-11.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">42.</div>
<div class="cr-content"><p>Keppeke GD, Prado MS, Nunes E, et al. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings antibodies. Clin Immunol 2016;173:149-56.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-24 - Centrosome</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306237-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306237-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306263-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306263-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473346982-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473346982-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600896-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600896-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152601-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152601-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>Centrioles</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Distinct centrioles (1-2/cell) in cytoplasm and at the poles of mitotic spindle.                                                             </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>pericentrin, ninein, Cep250, Cep110</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-24 pattern has low positive predictive value for any disease</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Within the spectrum of the SARD, the AC-24 pattern is found in patients with Raynaud&#x2019;s phenomenon, localized scleroderma, SSc, SLE and RA, either alone or in combination with other SSc-associated antibodies (102&#x2013;105)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include &#x3B1;-enolase, &#x3B3;-enolase, ninein, Cep-250, Mob1, PCM-1/2, pericentrin; specific immunoassays for these autoantibodies are currently not commercially available (104, 106&#x2013;108)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">102.</div>
<div class="cr-content"><p>Takahashi T, Asano Y, Hirakawa M, et al. Linear scleroderma with prominent multiple lymphadenopathy followed by the development of polymyositis: a case report and review of published work. J Dermatol 2016;43:1224-7.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">103.</div>
<div class="cr-content"><p>Howng SL, Chou AK, Lin CC, et al. Autoimmunity against hNinein, a human centrosomal protein, in patients with rheumatoid arthritis and systemic lupus erythematosus. Mol Med Rep 2011;4:825-30.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">104.</div>
<div class="cr-content"><p>Hamaguchi Y, Matsushita T, Hasegawa M, et al. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Mod Rheumatol 2015;25:798-801.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">105.</div>
<div class="cr-content"><p>Gavanescu I, Vazquez-Abad D, McCauley J, et al. Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol 1999;19:166-71.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">106.</div>
<div class="cr-content"><p>Fritzler MJ, Zhang M, Stinton LM, et al. Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr 2003;3.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">107.</div>
<div class="cr-content"><p>Rattner JB, Martin L, Waisman DM, et al. Autoantibodies to the centrosome (centriole) react with determinants present in the glycolytic enzyme enolase. J Immunol 1991;146:2341-4.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">108.</div>
<div class="cr-content"><p>Mack GJ, Rees J, Sandblom O, et al. Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. Arthritis Rheum 1998;41:551-8.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Possible association with infections; described in children with Mycoplasma pneumoniae infection (1)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Possible association with malignancies; autoantibodies reacting with antigens in centrosomes are frequently found in sera of patients with breast cancer (2, 3)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to &#x3B1;-enolase, &#x3B3;-enolase, Mob1, PCM-1/2, and pericentrin have been described in children with cerebellar ataxia after varicella infection; one patient with hyperthyroidism and vague muscle pain and one patient with Raynaud&#x2019;s phenomenon, both without evidence of a SARD, had antibodies to &#x3B1;-enolase and &#x3B3;-enolase (4.5)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>With respect to autoantibodies to ninein and Cep-250, there is no apparent correlation between serum autoantibody reactivity and the clinical diagnosis; reported in RA and SLE (6, 7)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e., antigen-specific immunoassays) and do not actually show correlations with the AC-24 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">1.</div>
<div class="cr-content"><p>Cimolai N, Mah D, Roland E. Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma pneumonia infection. J Neurol Neurosurg Psychiatry 1994;57:638-9.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">2.</div>
<div class="cr-content"><p>Madrid FF, Maroun MC, Olivero OA, et al. Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer 2015;15:407.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">3.</div>
<div class="cr-content"><p>Maroun MC, Olivero O, Lipovich L, et al. Anti-centrosome antibodies in breast cancer are the expression of autoimmunity. Immunol Res 2014;60:339-47.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">4.</div>
<div class="cr-content"><p>Fritzler MJ, Zhang M, Stinton LM, et al. Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr 2003;3:11.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">5.</div>
<div class="cr-content"><p>Rattner JB, Martin L, Waisman DM, et al. Autoantibodies to the centrosome (centriole) react with determinants present in the glycolytic enzyme enolase. J Immunol 1991;146:2341-4.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">6.</div>
<div class="cr-content"><p>Mack GJ, Rees J, Sandblom O, et al. Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. Arthritis Rheum 1998;41:551-8.</p></div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">7.</div>
<div class="cr-content"><p>Howng SL, Chou AK, Lin CC, et al. Autoimmunity against hNinein, a human centrosomal protein, in patients with rheumatoid arthritis and systemic lupus erythematosus. Mol Med Rep 2011;4:825-30.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-25 - Spindle fibers</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306309-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306309-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306310-1.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306310-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473308441-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473308441-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098226-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098226-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152656-0.jpg?1728523235" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152656-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>None</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        The spindle fibers between the poles are stained in mitotic cells, associated with cone-shaped decoration of the mitotic poles. Spindle fibers cover both NuMA-like and non-NuMA patterns. NuMA-like pattern has associated distinct nuclear speckles. Only non-NuMA patterns are shown here while NuMA-like patterns are shown in the NuMA-like group.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>HsEg5</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-25 pattern has low positive predictive value for any disease (109)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found very infrequently in a routine serology diagnostic setting (109)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigen recognized includes HsEg5; specific immunoassays for this autoantibody, or other spindle fiber targets, are currently not commercially available (110, 111)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">109.</div>
<div class="cr-content">Mozo L, Guti&#xE9;rrez C, G&#xF3;mez J. Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies. J Clin Immunol 2008;28:285-90.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">110.</div>
<div class="cr-content">Whitehead CM, Winkfein RJ, Fritzler MJ, et al. The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus. Arthritis Rheum 1996;39:1635-42.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">111.</div>
<div class="cr-content">Szalat R, Ghillani-Dalbin P, Jallouli M, et al. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: clinical and Immunological features: a propos of 40 new cases and review of the literature. Autoimmun Rev 2010;9:652-6.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>While AC-25 is not associated with a defined autoimmune disease, reactivity with HsEg5 is more commonly found in SjS and SLE (8, 9)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Note: Specific immunoassays for HsEg5 are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">Whitehead CM, Winkfein RJ, Fritzler MJ, et al. The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus. Arthritis Rheum 1996;39:1635-42.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">9.</div>
<div class="cr-content">Szalat R, Ghillani-Dalbin P, Jallouli M, et al. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: Clinical and immunological features: A propos of 40 new cases and review of the literature. Autoimmun Rev 2010;9:652-6. </div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-26 - NuMA-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306362-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306362-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306379-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306379-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098250-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098250-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1617152715-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1617152715-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625700320-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700320-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>MSA-1, centrophilin</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Nuclear speckled staining with spindle fibers.                                     </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>NuMA</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Approximately one-half of the patients with the AC-26 pattern have clinical features of a SARD (SjS, SLE, UCTD, limited SSc, or RA); the AC-26 pattern is also observed in patients with organ-specific autoimmune diseases and less frequently in non-autoimmune conditions, especially when in low titer (109, 111&#x2013;114)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found very infrequently in a routine serology diagnostic setting (109)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include NuMA, centrophilin, SP-H antigen and NMP-22; specific immunoassays for these autoantibodies are currently not commercially available (115)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">109.</div>
<div class="cr-content">Mozo L, Guti&#xE9;rrez C, G&#xF3;mez J, G&#xF3;mez Jes&#xFA;s. Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies. J Clin Immunol 2008;28:285-90.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">111.</div>
<div class="cr-content">Szalat R, Ghillani-Dalbin P, Jallouli M, et al. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: clinical and Immunological features: a propos of 40 new cases and review of the literature. Autoimmun Rev 2010;9:652-6.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">112.</div>
<div class="cr-content">Grypiotis P, Ruffatti A, Tonello M, et al. [Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]. Reumatismo 2002;54:232-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">113.</div>
<div class="cr-content">Price CM, McCarty GA, Pettijohn DE. NuMA protein is a human autoantigen. Arthritis Rheum 1984;27:774-9.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">114.</div>
<div class="cr-content">Bonaci-Nikolic B, Andrejevic S, Bukilica M, et al. Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance. J Clin Immunol 2006;26:438-46.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">115.</div>
<div class="cr-content">Compton DA, Szilak I, Cleveland DW. Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis. J Cell Biol 1992;116:1395-408.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-27 - Intercellular bridge</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306403-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306403-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306447-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306447-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306448-1.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306448-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473309430-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473309430-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1505098287-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1505098287-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>stem body, midbody</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Staining of the intercellular bridge that connects daughter cells by the end of cell division, but before cell separation.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>none</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-27 pattern has low positive predictive value for any disease (116)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found very infrequently in a routine serology diagnostic setting (117)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include, among other, CENP-E, CENP-F, TD60, MSA36, KIF-14, MKLP-1, MPP1/KIF20B, and INCENP; specific immunoassays for these autoantibodies are currently not commercially available (116, 118, 119)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">116.</div>
<div class="cr-content">Rattner JB, Mack GJ, Fritzler MJ. Autoantibodies to components of the mitotic apparatus. Mol Biol Rep 1998;25:143-55.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">117.</div>
<div class="cr-content">Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013;12:998-1003.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">118.</div>
<div class="cr-content">Humbel RLConrad K, ed. Autoantibodies to mitotic cells. In Dresden autoantibody symposium. Dresden Germany: Pabst Science, 2013: 327-39.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">119.</div>
<div class="cr-content">Rodriguez-Bayona B, Ruchaud S, Rodriguez C, et al. Autoantibodies against the chromosomal passenger protein INCENP found in a patient with Graham Little-Piccardi-Lassueur syndrome. J Autoimmune Dis 2007;4.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Incidentally described in patients with SSc, Raynaud&#x2019;s phenomenon, and malignancy (10-12)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to CENP-E, CENP-F, TD60, MSA36, KIF-14, and MKLP-1 have been described in patients with SSc (limited and diffuse), SLE, and malignancies (13, 14)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to INCENP have been described in a single patient with Graham-Little-Piccardi-Lasseur Syndrome (15)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to MPP1 /KIF20B (M-phase phosphoprotein 1) have been described in patients with idiopathic ataxia, other neurological syndromes and paroxysmal nocturnal haemoglobinuria (16, 17)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#xA0;</div>
<div class="cr-content isnote"><p>Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e., antigen-specific immunoassays) and do not actually show correlations with the AC-27 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">10.</div>
<div class="cr-content">Fritzler MJ, Ayer LM, Gohill J, et al. An antigen in metaphase chromatin and the midbody of mammalian cells binds to scleroderma sera. J Rheumatol 1987;14:291-4.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">11.</div>
<div class="cr-content">Tausche AK, Conrad K, Seidel W, et al. Anti-midbody antibodies as a possible predictive factor for a special limited or abortive form of systemic sclerosis? Ann Rheum Dis 2005;64:1237-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">12.</div>
<div class="cr-content">Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013;12:998-1003.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">13.</div>
<div class="cr-content">Rattner JB, Mack GJ, Fritzler MJ. Autoantibodies to components of the mitotic apparatus. Mol Biol Rep 1998;25:143-55.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">14.</div>
<div class="cr-content">Humbel RL. Autoantibodies to mitotic cells. in Dresden Autoantibody Symposium (eds. Conrad, K., et al.) 327-39 (Pabst Science, Dresden, Germany, 2013).</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">15.</div>
<div class="cr-content">Rodriguez-Bayona B, Ruchaud S, Rodriguez C, et al. Autoantibodies against the chromosomal passenger protein INCENP found in a patient with Graham Little-Piccardi-Lassueur syndrome. J Autoimmune Dis 2007;4:1.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">16.</div>
<div class="cr-content">Fritzler MJ, Kerfoot SM, Feasby TE, et al. Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein 1 (MPP-1). J Invest Med 2000;48:28-39.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">17.</div>
<div class="cr-content">Alahmad A, Preuss KD, Schenk J, et al. Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010;151:273-80. </div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-28 - Mitotic chromosomal</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1473306489-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306489-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1473306489-1.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1473306489-1.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1487962871-0.jpg?1728523236" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1487962871-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>chromosome coat protein, dividing cell antigen, mitotic chromosome autoantigen (MCA)</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        Punctate coloration of chromosomes in pro- and metaphase with no staining of interphase cells.                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>modified histone H3, MCA-1</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-28 pattern has low positive predictive value for any disease</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Found very infrequently in a routine serology diagnostic setting (120)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>Antigens recognized include DCA, MCA1, and MCA5; specific immunoassays for these autoantibodies are currently not commercially available (120&#x2013;122)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">120.</div>
<div class="cr-content">Gitlits VM, Macaulay SL, Toh BH, et al. Novel human autoantibodies to phosphoepitopes on mitotic chromosomal autoantigens (MCAs). J Investig Med 2000;48:172-82.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">121.</div>
<div class="cr-content">Blaschek M, Muller S, Youinou P. Anti-"dividing cell antigen" autoantibody: a novel antinuclear antibody pattern related to histones in systemic lupus erythematosus. J Clin Immunol 1993;13:329-38.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">122.</div>
<div class="cr-content">Rayzman VM, Sentry JW. MCA1 detection of histone H3 serine 10 phosphorylation, a novel biomarker for determination of mitotic indices. Hum Antibodies 2006;15:71-80.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to DCA have been described in patients with SLE (18)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to MCA1 have been described in patients with carcinoma (19)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content "><p>Autoantibodies to MCA5 have been described in patients with discoid lupus erythematosus, chronic lymphocytic leukemia, SjS, and polymyalgia rheumatica (20)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">18.</div>
<div class="cr-content">Blaschek M, Muller S, Youinou P. Anti-"dividing cell antigen" autoantibody: a novel antinuclear antibody pattern related to histones in systemic lupus erythematosus. J Clin Immunol 1993;13:329-38.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">19.</div>
<div class="cr-content">Rayzman VM, Sentry JW. MCA1 detection of histone H3 serine 10 phosphorylation, a novel biomarker for determination of mitotic indices. Hum Antibodies 2006;15:71-80.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">20.</div>
<div class="cr-content">Gitlits VM, Macaulay SL, Toh BH, et al. Novel human autoantibodies to phosphoepitopes on mitotic chromosomal autoantigens (MCAs). J Investig Med 2000;48:172-82.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
</table>
<table>
  <tr>
    <td>AC-29 - DNA topoisomerase I (topo I)-like</td>
  </tr>
</table>
<table class="table">
  <tr><td colspan="2" align="center">
                                        <a href="imgNew/prontas/1502477796-0.jpg?1728523237" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502477796-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1502478269-0.jpg?1728523237" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1502478269-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1520600972-0.jpg?1728523237" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1520600972-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625700370-0.jpg?1728523237" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700370-0.jpg" width="180" height="180"/></a><a href="imgNew/prontas/1625700423-0.jpg?1728523237" rel="grupo1" class="grouped_elements"><img src="imgNew/peq/1625700423-0.jpg" width="180" height="180"/></a>                                    </td>
                                </tr>
  <tr><td width="190"><strong>Previous Nomenclature</strong></td>
                                    <td>Scl-70-like, Scl-86, DNA Topo I</td>
                                </tr>
  <tr><td><strong>Description</strong></td>
                                    <td>
                                        <p>The Topo I-like pattern can comprise staining of five subcellular regions:</p>&#xD;
&#xD;
<div style="padding-left: 30px;">&#xD;
	<strong>1)</strong>	Prominent fine speckled AC-4 type nuclear staining in interphase cells.&#xD;
	<br/><strong>2)</strong>	Consistent strong fine speckled staining of condensed chromatin in mitotic cells. Depending on the serum dilution used, the mitotic chromatin staining may appear homogeneous.&#xD;
	<br/><strong>3)</strong>	Strong staining of nucleolar organizing region (NOR) associated on condensed chromosomes in mitotic cells. This NOR staining may be obscured by the bright chromosomal staining as NORs are not always on the same focal plane (see figure below).&#xD;
	<br/><strong>4)</strong>	Weak cytoplasmic staining in interphase (and mitotic) cells depicts a delicate network radiating from the perinuclear area towards the plasma membrane; in general, during titering sera to higher dilutions relatively more prominent cytoplasmic staining can be observed.&#xD;
	<br/><strong>5)</strong>	Variable nucleolar staining that can appear as a punctate nucleolar or perinucleolar staining in interphase cells. Nucleolar staining is not a universal feature of this pattern.&#xD;
</div>&#xD;
<p style="margin-top:10px;">&#xD;
This 5-element compound staining pattern has been observed in most commercial HEp-2 cell slides, but there may be some variations in the expression of each element according to the slide brand. The detection of all 5 elements may be a challenge especially when only using a single serum dilution (e.g. strong mitotic chromatin staining obscures NOR) or in many semi-automated systems when images are often selected on a single focal plane (e.g. NOR or cytoplasmic staining not in same focal plane as interphase nuclei).&#xD;
</p>&#xD;
&#xD;
<p>&#xD;
<u>Practical recommendation</u> how to routinely screen for AC-29 with a HEp-2 slide that show this pattern using a traditional microscope setting: if the above 1) and 2) features are observed on routine samples suggestive of the AC-29, the next step should be to look for 3) positive NOR staining by searching different focal planes for NORs on mitotic chromatins. Next, the presence of the 4) cytoplasmic staining and lastly 5) the nucleolar staining should be evaluated. In some HEp-2 slides, the nucleolar staining is only visible near the edge of the well.&#xD;
</p>&#xD;
&#xD;
<p>&#xD;
<em><strong>References</strong></em>&#xD;
</p>&#xD;
&#xD;
<p>&#xD;
Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford). 2009;48:632-7.&#xD;
</p>&#xD;
&#xD;
<p>&#xD;
Andrade LEC, Klotz W, Herold M, Conrad K, Ronnelid J, Fritzler MJ, von Muhlen CA, Satoh M, Damoiseaux J, de Melo Cruvinel W, Chan EKL. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med. 2018;56:1783-8.&#xD;
</p>&#xD;
&#xD;
<p>&#xD;
<img src="img/padroes/ac29.jpg" width="100%"/></p>&#xD;
&#xD;
<p>&#xD;
INOVA HEp-2 images illustrating the AC-29 pattern with staining in all 5 compartments. Panel A is a merged image from the other 3 panels (A', A'', A''') representing different optical sections/focal planes, each illustrating the unique stained structures not obvious in the other focal planes.  In addition to the obvious nucleoplasmic and mitotic condensed chromatin staining, panel A' illustrates two bright NORs in focus (arrow) on condensed chromatin in the mitotic cell; panel A'' shows another NOR in focus (arrow) in the same cell; A''' shows characteristic cytoplasmic (arrowhead) and weak perinucleolar staining (short arrow).&#xD;
</p>                                    </td>
                                </tr>
  <tr><td><strong>Antigen Association</strong></td>
                                    <td>DNA topoisomerase I</td>
                                </tr>
</table>
<table class="table">
  <style><![CDATA[
                                        ul.cr {
                                            padding: 0 1em;
                                            list-style: none;
                                        }

                                        ul.cr li {}

                                        ul.cr li:before {
                                            content: "";
                                            border-color: transparent #111;
                                            border-style: solid;
                                            border-width: 0.35em 0 0.35em 0.45em;
                                            display: block;
                                            height: 0;
                                            width: 0;
                                            left: -1em;
                                            top: 0.9em;
                                            position: relative;
                                        }

                                        ul.cr li:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        ul.cr li p {
                                            margin: 0;
                                        }

                                        .cr {
                                            display: flex;
                                            flex-direction: column;
                                            width: 100%;

                                        }

                                        .cr .cr-container {
                                            display: flex;
                                            flex-direction: row;
                                            align-items: flex-start;
                                            width: 100%;
                                            margin: 0 0 5px 0;
                                            padding: 3px 0;
                                        }

                                        .cr .cr-container:hover {
                                            background-color: rgba(166, 207, 53, 0.18);
                                        }

                                        .cr .cr-container .cr-marker {
                                            display: flex;
                                            padding: 0 6px 0 0;
                                            min-width: 35px;
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content.isnote {
                                            font-style: italic;
                                        }

                                        .cr .cr-container .cr-marker.cr-number {
                                            justify-content: flex-end;
                                        }

                                        .cr .cr-container .cr-content p {
                                            margin: 0;
                                            padding: 0;
                                        }

                                        .cr .cr-container .cr-content {
                                            display: flex;
                                            flex-direction: column;
                                        }
                                    ]]></style>
  <!-- First Level Paragraphs -->
  <tr><td style="width: 100%; text-align: center;">
                                            <strong>Clinical Relevance</strong>
                                            <br/><em>First level information</em>
                                            <br/><a href="#" class="openModalCR" style="border-radius: 15px; margin: auto; width: fit-content; padding: 5px 10px;"><i class="fa fa-info-circle"/>About Clinical Relevance &amp; List of Abbreviations                                            </a>
                                        </td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>The AC-29 pattern is highly specific for SSc, in particular with diffuse cutaneous SSc and more aggressive forms of SSc (14, 18, 23)</p></div>
</div>
<div class="cr-container">
<div class="cr-marker">&#x25B6;</div>
<div class="cr-content " testejc="true"><p>If SSc is clinically suspected, it is recommended to perform a follow-up test for anti-Topoisomerase I (formerly Scl-70) antibodies; the anti-Topoisomerase I antibodies are included in the classification criteria for SSc and the antigen is included in routine ENA profiles (8, 23, 79)</p></div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- First Level References -->
  <tr><td style="text-align: center;"><em>First level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container">
<div class="cr-marker cr-number">8.</div>
<div class="cr-content">van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">14.</div>
<div class="cr-content">Andrade LEC, Klotz W, Herold M, et al. International consensus on antinuclear antibody patterns: definition of the ac-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 2018;56:1783-8.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">18.</div>
<div class="cr-content">Dellavance A, Gallindo C, Soares MG, et al. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology 2009;48:632-7.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">23.</div>
<div class="cr-content">Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 2012;64:358-67.</div>
</div>
<div class="cr-container">
<div class="cr-marker cr-number">79.</div>
<div class="cr-content">Basu D, Reveille JD. Anti-scl-70. Autoimmunity 2005;38:65-72.</div>
</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                <div class="cr-container" style="text-align: center;">None</div>                                            </div>
                                        </td>
                                    </tr>
  <!-- Second Level Paragraphs -->
  <tr><td style="text-align: center;"><em>Second level information references</em></td>
                                    </tr>
  <tr><td>
                                            <div class="cr">
                                                None                                            </div>
                                        </td>
                                    </tr>
</table>
